Stay updated with the latest serotype news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on serotype topics.
Qdenga vaccine against dengue (image is for representation purposes only) AI generated image ShowQuick Read Summary is AI-generated, newsroom-reviewed * Qdenga dengue vaccine expected to launch in India by 2026 after regulatory approval * Vaccine developed by Takeda Pharma, to be made in India with Biological E under Make-in-India * Qdenga requires two doses and protects against all dengue serotypes, including prior infections Did our AI summary help? Let us know. Switch To Beeps Mode ...Read More >
New Delhi: Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 centres in India, according to ICMR scientists. So far, 8,000 participants in various centres at Pune, Chennai, Kolkata, Delhi and Bhubaneswar, among others, have received either the vaccine or a placebo as part of the trial sponsored by the Indian Council of Medical Research (ICMR) and Pana ...Read More >
Representative Image: Currently, there is no antiviral treatment or licensed vaccine against dengue in India | Image: Bloomberg Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 centres in India, according to ICMR scientists. So far, 8,000 participants in various centres at Pune, Chennai, Kolkata, Delhi and Bhubaneswar among others have received eith ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.